SUNNYVALE, Calif., Jan. 12 /PRNewswire/ -- Biocircuits Corporation
(Nasdaq: BIOC) announced today that, based on currently available information,
it expects its fourth quarter revenues to be approximately $1,150,000.  The
Company reported revenues of $215,000 for the fourth quarter 1996.
    Biocircuits anticipates the net loss for the fourth quarter 1997 to be in
the range of $0.06 per share to $0.09 per share.  In the fourth quarter 1996,
the Company's net loss was $0.49 per share.  The Company expects to report
fourth quarter results on January 28.
    "In the fourth quarter, revenues include shipments to distributors through
mid-November when Becton Dickinson assumed the sales and marketing
responsibilities for the IOS(R) system.  In November and December our revenues
include initial shipments of product to Becton Dickenson as well as the
$750,000 one time signing fee received from Becton Dickinson upon the
completion of the marketing and manufacturing agreement," said John Kaiser,
President and CEO.
    The IOS system is the first easy to use and economical system for
performing immunoassays in the physician's office.  Although approximately
36,000 sites currently have the requisite moderate complex license for
performing such tests, most send the testing out to large laboratories since
an appropriate system performing such tests has not been available.
Currently, four cartridges are available for use on the system, a T4/T Uptake
combination, TSH, T4/TSH combination and a Quantitative hCG cartridge.  In
addition, the free T4 cartridge and a Digoxin cartridge are in various stages
of clinical evaluation and a PSA cartridge is in late development stages.
    Actual results may differ materially from the above forward-looking
statements due to a number of important factors, and will be dependent upon
Becton Dickinson successfully manufacturing the IOS instrument and marketing
the existing and proposed products, as well as the timely development and
regulatory approval of additional products by Biocircuits.  These factors are
more fully discussed in the Company's most recent reports on Form 10-K for
year ended December 31, 1996 and the Company's resale Registration Statement
No. 333-26079 dated August 22, 1997.

Link to this page: